Equities
  • Price (EUR)87.01
  • Today's Change-0.19 / -0.22%
  • Shares traded0.00
  • 1 Year change-17.95%
  • Beta--
Data delayed at least 15 minutes, as of Aug 12 2022 16:35 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for use by people with diabetes and by healthcare providers. Its Dexcom G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an application on the patient's mobile device to wirelessly transmit glucose information to the cloud and then to applications on the mobile devices of up to five designated recipients. Its Dexcom Real-Time API enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices. Its other products include Dexcom ONE and Dexcom G7.

  • Revenue in USD (TTM)2.67bn
  • Net income in USD199.70m
  • Incorporated1999
  • Employees6.30k
  • Location
    Dexcom Inc6340 Sequence DrSAN DIEGO 92121-4356United StatesUSA
  • Phone+1 (858) 200-0200
  • Fax+1 (302) 636-5454
  • Websitehttps://www.dexcom.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.